68Ga-DOTA-TATE PET vs. 123I-MIBG in identifying malignant neural crest tumours

Molecular Imaging and Biology

Volumn 13, Issue 4, 2011, Pages 769-775

  Naji, Meeran ^a   Zhao, Chunlei ^b   Welsh, Sarah J ^a   Meades, Richard ^a   Win, Zarni ^a   Ferrarese, Annalisa ^c   Tan, Tricia ^a   Rubello, Domenico ^c   Al Nahhas, Adil ^a  

^a IMPERIAL COLLEGE HEALTHCARE NHS TRUST   (United Kingdom)

^b THE SECOND AFFILIATED HOSPITAL OF ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

^c 'Santa Maria della Misericordia' Hospital   (Italy)

Author keywords

123I MIBG scintigraphy; 68Ga DOTA TATE PET; Malignant neural crest tumours

Indexed keywords

(3 IODOBENZYL)GUANIDINE I 123; 1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID GA 68; GADOTERIC ACID; UNCLASSIFIED DRUG; (3 IODOBENZYL)GUANIDINE; 68GA DOTATATE; 68GA-DOTATATE; DIAGNOSTIC AGENT; ORGANOMETALLIC COMPOUND; RADIOACTIVE IODINE; SDHB PROTEIN, HUMAN; SUCCINATE DEHYDROGENASE;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; BRAIN CANCER; CANCER DIAGNOSIS; CLINICAL ARTICLE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; CONTROLLED STUDY; DRUG SENSITIVITY; FEMALE; GENE; GENE EXPRESSION; GENETIC SCREENING; HUMAN; IMAGE ANALYSIS; INTERMETHOD COMPARISON; MALE; MALIGNANT NEURAL CREST TUMOR; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; PARAGANGLIOMA; PHEOCHROMOCYTOMA; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SDHB GENE; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; THYROID MEDULLARY CARCINOMA; ADRENAL TUMOR; COMPARATIVE STUDY; GENETICS; LYMPH NODE METASTASIS; METHODOLOGY; MIDDLE AGED; MUTATION; PATHOLOGY; SCINTISCANNING;

3-IODOBENZYLGUANIDINE; ADRENAL GLAND NEOPLASMS; ADULT; AGED; FEMALE; HUMANS; IODINE RADIOISOTOPES; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; MUTATION; ORGANOMETALLIC COMPOUNDS; PARAGANGLIOMA; POSITRON-EMISSION TOMOGRAPHY; RETROSPECTIVE STUDIES; SUCCINATE DEHYDROGENASE; YOUNG ADULT;

EID: 80052627039     PISSN: 15361632     EISSN: 18602002     Source Type: Journal    
DOI: 10.1007/s11307-010-0396-8     Document Type: Article

References (36)

1. Neumann HP, Bausch B, McWhinny SR, Bender BU, Gimm O, Franke G et al (2002) Germ-line mutations in nonsyndromic pheochromocytoma. N Engl J Med 346:1459-1466 (Pubitemid 34755714)
2. O'Riordain D, Young WF, Grant CS, Carney JA, van Heerden (1996) Clinical spectrum and outcome of functional extraadrenal paraganglioma. World J Surg 20:916-922 (Pubitemid 26281923)
3. Reisch N, Peczkowska M, Januszewicz A, Neumann HP (2006) Pheochromocytoma: Presentation, diagnosis and treatment. J Hypertens 24:2331-2339 (Pubitemid 44684675)
4. 68Ga-DOTATATE PET in neuroectodermal tumours: First experience. Nucl Med Commun 28:359-363 (Pubitemid 46569168)
5. 111In- pentetreotide scintigraphy in the localization of non-metastatic and metastatic pheochromocytoma. J Nucl Med 49:1613-1619
6. Lewigton VJ (2003) Targeted radionuclide therapy for neuroendocrine tumours. Endocr-Relat Cancer 10:497-501
7. Kwekkeboom DJ, Mueller-Brand J, Paganelli G, Anthony LB, Pauwels S, Kvols LK et al (2005) Overview of results of peptide receptor radionuclide therapy with 3 radiolabeled somatostatin analogs. J Nucl Med 46(Suppl 1):62S-66S (Pubitemid 47619020)
8. 131I-metaiodobenzylguanidine uptake in patients with neural crest tumours correlate with clinical outcome? Nucl Med Commun 22:257-260 (Pubitemid 32222643)
9. Pasini B, Stratakis CA (2009) SDH mutations in tumorigenesis and inherited endocrine tumours: Lesson from the phaeochromocytomaparaganglioma syndromes. J Intern Med 266(1):19-42
10. Yankovskaya V, Horsefield R, Törnroth S, Luna-Chavez C, Miyoshi H, Ĺger C et al (2003) Architecture of succinate dehydrogenase and reactive oxygen species generation. Science 299:700-704 (Pubitemid 36159483)
11. Astuti D, Latif F, Dallol A, Dahia PL, Douglas F, George E et al (2001) Gene mutations in the succinate dehydrogenase subunit SDHB cause susceptibility to familial pheochromocytoma and to familial paraganglioma. Am J Hum Genet 69:49-54 (Pubitemid 32614017)
12. Baysal BE, Ferrell RE, Willett-Brozick JE, Lawrence EC, Myssiorek D, Bosch A et al (2000) Mutations in SDHD, a mitochondrial complex II gene, in hereditary paraganglioma. Science 287:848-851 (Pubitemid 30084326)
13. Niemann S, Muller U (2000) Mutations in SDHC cause autosomal dominant paraganglioma, type 3. Nat Genet 26:268-270
14. Karagiannis A, Mikhailidis DP, Athyros VG, Harsoulis F (2007) Pheochromocytoma: An update on genetics and management. Endocr- Relat Cancer 14:935-956 (Pubitemid 351252428)
15. Benn DE, Gimenez-Roqueplo A-P, Reilly JR, Bertherat J, Burgess J, Byth K et al (2006) Clinical presentation and penetrance of pheochromocytoma/ paraganglioma syndromes. J Clin Endocrinol Metab 91:27-836
16. Klein RD, Jin L, Rumilla K, Young WF Jr, Lloyd RV (2008) Germline SDHB mutations are common in patients with apparently sporadic sympathetic paragangliomas. Diagn Mol Pathol 17(2):94-100
17. Bryant J, Farmer J, Kessler LJ, Townsend RR, Nathanson KL (2003) Pheochromocytoma: The expanding genetic differential diagnosis. J Natl Cancer Inst 95(16):1196-1204 (Pubitemid 37069549)
18. Chrisoulidou A, Kaltsas G, Ilias I, Grossman AB (2007) The diagnosis and management of malignant phaeochromocytoma and paraganglioma. Endocr-Relat Cancer 14(3):569-585 (Pubitemid 350074048)
19. Ilias I, Pacak K (2004) Current approaches and recommended algorithm for the diagnostic localization of pheochromocytoma. J Clin Endocrinol Metab 89:479-491 (Pubitemid 38269845)
20. Go AS (1998) Refining probability: An introduction to the use of diagnostic tests. In: Friedland DJ (ed) Evidence-based medicine. McGraw-Hill, New York, pp 12-33
21. 131Iiodobenzylguanidine. J Nucl Med 21:349-353 (Pubitemid 10100562)
22. Beierwaltes WH (1991) Endocrine imaging: Parathyroid, adrenal cortex and medulla, and other endocrine tumors. Part II. J Nucl Med 32:1627-1639
23. McEwan AJ, Shapiro B, Sisson JC, Beierwaltes WH, Ackery DM (1985) Radioiodobezylguanidine for the scintigraphic location and therapy of adrenergic tumors. Semin Nucl Med 15:132-153
24. Shulkin BL, Ilias I, Sisson JC, Pacak K (2006) Current trends in functional imaging of pheochromocytomas and paragangliomas. Ann NY Acad Sci 1073:374-382 (Pubitemid 44912032)
25. 18F-fluorodeoxyglucose positron emission tomography improve clinical decision making in suspected phaeochromocytoma. Ann Surg Oncol 13(2):187-197 (Pubitemid 43157413)
26. Reynolds S, Lewington V (2008) Radionuclide imaging of phaeochromocytoma and paraganglioma. Imaging 34:21-24
27. 123I- metaiodobenzylguanidine for scintigraphic detection of head and neck paragangliomas. J Nucl Med 49:1232-1237
28. Ilias I, Pacak K (2008) A clinical overview of pheochromocytomas/ paragangliomas and carcinoid tumors. Nucl Med Biol 35(Suppl 1):S27-S34
29. Brink I, Hoegerle S, Klisch J, Bley TA (2005) Imaging of pheochromocytoma and paraganglioma. Fam Cancer 4(1):61-68 (Pubitemid 40754847)
30. Maurea S, Mainolfi C, Wang H, Varrella P, Panico MR, Klain M et al (1996) Positron emission tomography (PET) with fludeoxyglucose F 18 in the study of adrenal masses: Comparison of benign and malignant lesions. Radiol Med 92:782-787 (Pubitemid 27121932)
31. Shulkin BL, Thompson NW, Shapiro B, Francis IR, Sisson JC (1999) Pheochromocytomas: Imaging with 2-[fluorine-18]fluoro-2-deoxy-Dglucose PET. Radiology 212:35-41
32. 18F] FDG and 82Rb. J Comput Assist Tomogr 20:312-316
33. 18F]-fluorodopamine- and [(123)I]-metaiodobenzylguanidine- negative metastatic pheochromocytoma sites. Nucl Med Commun 27:31-36 (Pubitemid 44391837)
34. 123I-MIBG scintigraphy in the localization of pheochromocytoma and paraganglioma. J Clin Endocrinol Metab 94(12):4757-4767
35. Khan S, Lloyd C, Szyszko T, Win Z, Rubello D, Al-Nahhas A (2008) PET imaging in endocrine tumours. Minerva Endocrinol 33 (2):41-52
36. Al-Nahhas A, Win Z, Szyszko T, Singh A, Khan S, Rubello D (2007) What can gallium-68 PET add to receptor and molecular imaging? Eur J Nucl Med Mol Imaging 34(12):1897-1901 (Pubitemid 350212142)